Content area
Full Text
The U.S. FDA has approved a new imaging agent for the detection of prostate cancer, providing a more effective imaging approach to detect the spread of cancer to other parts of the body. The agent, called 18F-DCFPyL (PyL), is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA and also the first commercially available PSMA...